ID: ALA1366

Max Phase: Approved

First Approval: 1985

Molecular Formula: C20H34AuO9PS

Molecular Weight: 678.49

Molecule Type: Small molecule

Molecule Features

Natural Product: No

Oral: Yes

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: Yes

Chirality: Yes

Availability: Yes

Prodrug: No

Properties

Molecular Weight: 678.49

Molecular Weight (Monoisotopic): 678.1327

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Blythin DJ, Kaminski JJ, Domalski MS, Spitler J, Solomon DM, Conn DJ, Wong SC, Verbiar LL, Bober LA, Chiu PJ..  (1986)  Antiinflammatory activity of substituted 6-hydroxypyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-triones. Atypical nonsteroidal antiinflammatory agents.,  29  (6): [PMID:3086558] [10.1021/jm00156a032]

2. Fujita M, Seki T, Ikeda N..  (2002)  Synthesis and bioactivities of novel bicyclic thiophenes and 4,5,6,7-tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.,  12  (15): [PMID:12113803] [10.1016/s0960-894x(02)00332-3]

3. Tobe M, Isobe Y, Tomizawa H, Matsumoto M, Obara F, Nagasaki T, Hayashi H..  (2001)  Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation.,  11  (4): [PMID:11229767] [10.1016/s0960-894x(00)00718-6]

4. Chircorian A, Barrios AM..  (2004)  Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I).,  14  (20): [PMID:15380210] [10.1016/j.bmcl.2004.07.073]

5. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ..  (2010)  Developing structure-activity relationships for the prediction of hepatotoxicity.,  23  (7): [PMID:20553011] [10.1021/tx1000865]

6. Ekins S, Williams AJ, Xu JJ..  (2010)  A predictive ligand-based Bayesian model for human drug-induced liver injury.,  38  (12): [PMID:20843939] [10.1124/dmd.110.035113]

7. Unpublished dataset, 

8. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

9. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

10. Derbyshire ER, Prudêncio M, Mota MM, Clardy J..  (2012)  Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,  109  (22): [PMID:22586124] [10.1073/pnas.1118370109]

11. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

12. Bakmiwewa SM, Fatokun AA, Tran A, Payne RJ, Hunt NH, Ball HJ..  (2012)  Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.,  22  (24): [PMID:23122865] [10.1016/j.bmcl.2012.10.010]

13. Kaiser M, Mäser P, Tadoori LP, Ioset JR, Brun R.. Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning,  [10.6019/CHEMBL3392926]

14. Klug DM, Gelb MH, Pollastri MP..  (2016)  Repurposing strategies for tropical disease drug discovery.,  26  (11): [PMID:27080183] [10.1016/j.bmcl.2016.03.103]

15. WHO Anatomical Therapeutic Chemical Classification, 

16. British National Formulary (72nd edition), 

17. DrugMatrix,  [10.6019/CHEMBL3885881]

18. Unpublished dataset, 

19. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard.  (2020)  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication,  [10.1101/2020.04.03.023846]

20. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

Source

Source(11):

• Scientific Literature
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• USP Dictionary of USAN and International Drug Names
• Drugs for Neglected Diseases Initiative (DNDi)
• DrugMatrix
• Harvard Malaria Screening
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• SARS-CoV-2 Screening Data 2020-21
• Fraunhofer HDAC6